Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical trials. Muse is the first outcome of the collaboration between the three companies, which aims to combine their pharma expertise and AI models to accelerate drug development and ultimately speed up breakthrough therapies to patients. Muse aims to shorten patient recruitment by accelerating recruitment strategy + content creation from months to just minutes.

Muse aims to analyze extensive scientific literature, real world evidence and unique insights on diseases and patient populations, delivering comprehensive research, strategic opportunities, and faster preparation of patient recruitment strategies - accomplishing with a single AI tool what typically requires large teams of experts and multiple layers of manual review. At scale, this AI-driven development approach can accelerate the delivery of new medicines and reshape healthcare worldwide. Muse is just the start--one of the many AI innovations we're building for drug development." Developed jointly by the three companies leveraging multiple OpenAI models, Muse is designed for use across a wide range of therapeutic areas.

Both Sanofi and Formation Bio plan to implement Muse in upcoming clinical trials, with Sanofi leading the initial deployment in Phase 3 studies for multiple sclerosis (MS). For this rollout, Sanofi will provide data and expertise on MS, leveraging its deep experience in delivering innovative treatments to support patients affected by this debilitating condition.use develops tailored strategies and materials designed for diverse patient populations, including historically underrepresented groups, in order to enhance inclusiveness and representation in clinical trials. This approach can expand participation and ultimately capture broader trial data, contributing to more reliable, generalizable insights that better reflect the needs of all patients.

Additionally, Muse includes an LLM agent that incorporates Institutional Review Board (IRB) and regulatory guidelines, aiming to automatically generate high-quality materials that keep compliance best practices in mind. This feature, when combined with human experts in the loop, reduces the risk of regulatory setbacks, promoting faster, more efficient trial progression. AI safety and data privacy are embedded throughout Muse's development and deployment, reflecting all three companies' commitment to the responsible use of AI.

Muse relies on research publications and other public and proprietary data sources, none of which contain personally identifiable information (PII).